A5013566053- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Genital Health and Disease
- Advanced Radiotherapy Techniques
- Hemoglobinopathies and Related Disorders
- Urinary Bladder and Prostate Research
- Blood groups and transfusion
- Bladder and Urothelial Cancer Treatments
- Urologic and reproductive health conditions
- Iron Metabolism and Disorders
- Urological Disorders and Treatments
- COVID-19 Clinical Research Studies
- Hematopoietic Stem Cell Transplantation
- Blood donation and transfusion practices
- SARS-CoV-2 and COVID-19 Research
- Circular RNAs in diseases
- Blood transfusion and management
- Mechanical Circulatory Support Devices
- Blood disorders and treatments
- Colorectal Cancer Surgical Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Cerebrospinal fluid and hydrocephalus
- Radiopharmaceutical Chemistry and Applications
- HIV, Drug Use, Sexual Risk
- Neutropenia and Cancer Infections
National Institutes of Health Clinical Center
2019-2025
Government of the United States of America
2023
Georgetown University
2013-2017
MedStar Georgetown University Hospital
2016-2017
Georgetown University Medical Center
2013-2014
Abstract Background Stereotactic body radiation therapy (SBRT) delivers fewer high-dose fractions of which may be radiobiologically favorable to conventional low-dose commonly used for prostate cancer radiotherapy. We report our early experience using SBRT localized cancer. Methods Patients treated with from June 2008 May 2010 at Georgetown University Hospital carcinoma, or without the use androgen deprivation (ADT), were included in this retrospective review data that was prospectively...
Prostate cancer (PCa) is the most common type of in men United States, which disproportionately affects African American descents. While metastasis cause death among PCa patients, no specific markers have been assigned to severity and ethnic biasness disease. MicroRNAs represent a promising new class biomarkers owing their inherent stability resilience. In present study, we investigated potential miRNAs that can be used as and/or therapeutic targets provide insight into PCa. PCR array was...
Abstract Background Characterizing the kinetics of antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical importance developing strategies that may mitigate public health burden disease 2019 (COVID-19). We conducted a prospective, longitudinal analysis COVID-19 convalescent plasma donors at multiple time points over an 11-month period determine how circulating levels change following natural infection. Methods From April 2020 February 2021, we enrolled...
Abstract Several variants of SARS-CoV-2 have emerged. Those with mutations in the angiotensin-converting enzyme (ACE2) receptor binding domain (RBD) are associated increased transmission and severity. In this study, we developed both antibody quantification functional neutralization assays. Analyses COVID-19 convalescent diagnostic cohorts strongly support use RBD levels as an excellent surrogate to biochemical activities. Data further revealed that samples from mRNA vaccinated individuals...
Stereotactic body radiation therapy (SBRT) delivers high doses of to the prostate while minimizing adjacent normal tissues. Large fraction sizes may increase risk functional decrements. Treatment-related bother be more important a patient than treatment-related dysfunction. This study reports on patient-reported outcomes following SBRT for clinically localized cancer. Between August 2007 and July 2011, 228 consecutive hormone-naïve patients with cancer were treated 35–36.25 Gy delivered...
Patients with large prostate volumes have been shown to higher rates of genitourinary and gastrointestinal toxicities after conventional radiation therapy for cancer. The efficacy toxicity stereotactic body (SBRT), which delivers fewer high-dose fractions treatment, is unknown volume cancer patients. We report our early experience using SBRT localized in patients volumes. 57 ≥50 cm3 prior treatment carcinoma a minimum follow up two years were included this retrospective review prospectively...
Late urinary symptom flare has been shown to occur in a small subset of men treated with ultra- hypofractionated stereotactic body radiotherapy (SBRT) for prostate cancer. The purpose this study was use normal tissue complication probability modeling an effort derive SBRT specific dosimetric predictor's late flare.Two hundred and sixteen were localized cancer using SBRT. A dose 35-36.25 Gy 5 fractions delivered the proximal seminal vesicles. Functional surveys conducted before after...
Abstract Background Erectile dysfunction after prostate radiation therapy remains an ongoing challenge and critical quality of life issue. Given the higher dose per fraction using stereotactic body (SBRT) there is concern that post-SBRT impotency would be than conventional approaches. This study sought to evaluate potency preservation sexual function following SBRT for cancer. Methods Between February 2008 March 2011, 216 men with clinically localized cancer were treated definitively...
Stereotactic body radiation therapy (SBRT) is emerging as a minimally invasive alternative to brachytherapy deliver highly conformal, dose--escalated (RT) the prostate. SBRT alone may not adequately cover tumor extensions outside prostate commonly seen in unfavorable cancer. External beam (EBRT) with high dose rate boost proven effective for This study reports on early prostate-specific antigen and cancer-specific quality of life (QOL) outcomes cohort patients treated intensity-modulated...
Stereotactic body radiation therapy (SBRT) is increasingly utilized as primary treatment for clinically localized prostate cancer. While acute post-SBRT urinary symptoms are well recognized, the late genitourinary toxicity of SBRT has not been fully described. Here, we characterize clinical features symptom flare and recommend conservative management approaches that may alleviate associated bother.Between February 2008 August 2011, 216 men with cancer were treated definitively at Georgetown...
Abstract Background and Objectives Granulocyte transfusion supports patients with severe neutropenia. Maintaining a pool of eligible donors optimizing donation frequency are essential for ensuring an adequate supply while safeguarding donor well‐being. This study investigates the impact on erythrogram parameters, focusing sex‐specific differences. Study Design Methods We conducted retrospective analysis 343 successive granulocyte collections from 65 apheresis over 11 years (2012–2023)....
Obstructive voiding symptoms (OVS) are common following prostate cancer treatment with radiation therapy. The risk of urinary retention (UR) hypofractionated radiotherapy has yet to be fully elucidated. This study sought evaluate OVS and UR requiring catheterization SBRT for cancer. Patients treated localized from February 2008 July 2011 at Georgetown University were included in this study. Treatment was delivered using the CyberKnife® doses 35 Gy-36.25 Gy 5 fractions. prospectively scored...
Proctitis after radiation therapy for prostate cancer remains an ongoing clinical challenge and critical quality of life issue. SBRT could minimize rectal toxicity by reducing the volume rectum receiving high doses offers potential radiobiologic benefits hypofractionation. This study sought to evaluate incidence severity proctitis following cancer. Between February 2008 July 2011, 269 men with clinically localized were treated definitively monotherapy at Georgetown University Hospital. All...
Hematuria following prostate radiotherapy is a known toxicity that may adversely affect patient's quality of life. Given the higher dose radiation per fraction using stereotactic body therapy (SBRT) there concern post-SBRT hematuria would be more common than with alternative approaches. Herein, we describe incidence and severity for cancer at our institution. Two hundred eight consecutive patients treated SBRT monotherapy least three years follow-up were included in this retrospective...
Urinary incontinence (UI) following prostate radiotherapy is a rare toxicity that adversely affects patient's quality of life. This study sought to evaluate the incidence UI stereotactic body radiation therapy (SBRT) for cancer.Between February, 2008 and October, 2010, 204 men with clinically localized cancer were treated definitively SBRT at Georgetown University Hospital. Patients 35-36.25 Gray (Gy) in 5 fractions delivered CyberKnife (Accuray). was assessed via Expanded Prostate Index...
Background. Stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. However, specific antigen (PSA) kinetics after SBRT have not been well characterized. The purpose of this study was to analyze the trend in PSA decline following robotic from a prospective cohort patients.Material and methods. In total 175 patients were treated definitively cancer dose 35–36.25 Gy 5 fractions using absence androgen deprivation therapy (ADT). testosterone...
Background: Stereotactic body radiation therapy (SBRT) delivers high doses of to the prostate while minimizing adjacent critical organs. Large fraction sizes may increase urinary morbidity due unavoidable treatment prostatic urethra. This study reports rates acute following SBRT for localized cancer with prophylactic alpha-adrenergic antagonist utilization and urethral dose reduction (UDR). Methods: From April 2013 September 2014, 102 patients clinically were treated robotic a total 35-36.25...
Abstract Background In December 2021, the U.S. Food and Drug Administration published a letter to clinical laboratory staff healthcare providers detailing risk of false Rapid Plasma Reagin (RPR) when using Bio‐Rad Laboratories BioPlex 2200 Syphilis Total & RPR kit in people who had received COVID‐19 vaccination; Treponema pallidum particle agglutination assays did not appear be impacted by this issue. We evaluated reactivity rates syphilis screening with negative confirmatory testing at...
Proctitis following prostate cancer radiation therapy is a primary determinant of quality life (QOL). While previous studies have assessed acute rectal morbidity at 1 month after stereotactic body radiotherapy (SBRT), little data exist on the prevalence and severity within first week treatment. This study reports bowel SBRT.Between May 2013 August 2014, 103 patients with clinically localized were treated 35-36.25 Gy in five fractions using robotic SBRT delivered prospective clinical trial....
BACKGROUND Molecular markers that can discriminate indolent cancers from aggressive ones may improve the management of prostate cancer and minimize unnecessary treatment. Aberrant DNA methylation is a common epigenetic event in HOXD3 promoter hypermethylation (H3PH) has been found cancer. Our objective was to evaluate relationship between H3PH clinicopathologic features screening biopsies. METHODS Ninety-two patients who underwent biopsy at our institution October 2011 May 2012 were included...
Background: Irritative voiding symptoms are common in elderly men and following prostate radiotherapy. The impact of hypofractionated treatment on irritative has not been determined. This study sought to evaluate urgency, frequency nocturia SBRT for cancer. Methods: Patients treated with monotherapy localized cancer from August 2007 July 2011 at Georgetown University Hospital were included this study. Treatment was delivered using the CyberKnife® doses 35 Gy-36.25 Gy 5 fractions....